ストックスクリーナーアプリを入手
1.77
1.67%
-0.03
アフターアワーズ：
1.77
前日終値:
$1.80
開ける：
$1.8
24時間の取引高:
426.95K
Relative Volume:
0.21
時価総額：
$281.43M
収益：
$10.00M
当期純損益:
$-29.47M
株価収益率:
-8.85
EPS:
-0.2
ネットキャッシュフロー:
$-21.55M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+1.72%
6か月 パフォーマンス:
-24.68%
1年 パフォーマンス:
-55.75%
1日の値動き範囲:
$1.76
$1.8027
1週間の範囲:
$1.705
$1.88
52週間の値動き範囲:
$1.47
$4.72
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
名前
Mereo Biopharma Group Plc Adr
セクター
電話
4403330237300
住所
ONE CAVENDISH PLACE, LONDON
MREO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.77 | 286.37M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-27 | 開始されました | JP Morgan | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-13 | 再開されました | BTIG Research | Buy |
| 2022-08-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Needham | Buy |
すべてを表示
Mereo Biopharma Group Plc Adr (MREO) 最新ニュース
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Adage Capital Partners GP L.L.C. Has $3.83 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Receives $7.40 Consensus PT from Brokerages - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Frazier Life Sciences Management L.P. Increases Stock Holdings in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
Upcoming Events - FinancialContent
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
About Us - FinancialContent
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Analysts Set Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Price Target at $7.20 - MarketBeat
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Investors in Mereo BioPharma Group plc (MREO) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
MREO ACTIVE INVESTIGATION: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky Now - ACCESS Newswire
Mereo Biopharma Group Plc Adr (MREO) 財務データ
収益
当期純利益
現金流量
EPS
2.43%
大文字化:
|
ボリューム (24 時間):